+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
MALE
ID07115914

Study of PSMA PET Scan Added to MRI for Monitoring Prostate Cancer After Partial Gland Ablation

Led by University of Chicago · Updated on 2026-02-17

62

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how adding a PSMA PET scan to standard multiparametric MRI can improve detection of prostate cancer recurrence in men who have had focal therapy. This study focuses on men with prostate cancer who have undergone partial gland ablation and aims to improve imaging methods to better identify cancer recurrence after treatment. The research is sponsored by the University of Chicago and funded by Blue Earth Diagnostics, a molecular imaging company. Participants will receive a PSMA PETCT scan in addition to their routine MRI scans during the 12 months following focal therapy. Focal therapy itself is part of standard clinical care and not provided by the study. Participants will also give blood, urine, and optionally tissue samples for research purposes. Quality of life questionnaires will be completed to assess participant well-being. During the study, participants will attend visits for about one year after focal therapy for imaging and monitoring. Researchers will measure whether adding the PSMA PET scan improves cancer detection compared to MRI alone. Secondary goals include evaluating the value of PSMA PET combined with MRI and PSA testing in diagnosing significant cancer recurrence. Safety and adherence will be monitored through regular clinical follow-up and sample collections.

CONDITIONS

Brief Title

PSMA PET for Surveillance After Focal Therapy

Research Team

A

Abhinav Sidana, MD

A

Abhinav Sidana, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here